Top Class Actions’s website and social media posts use affiliate links. If you make a purchase using such links, we may receive a commission, but it will not result in any additional charges to you. Please review our Affiliate Link Disclosure for more information.
Plaintiff Roy Vidrine has filed a Januvia lawsuit against drug manufacturer Merck, alleging that their type-2 diabetes drug caused him to develop pancreatic cancer.
Vidrine was initially prescribed Januvia in December 2012, and continued to use the drug through February 2013. However, in April 2013, Vidrine was diagnosed with pancreatic cancer. His Januvia lawsuit alleges that the drug caused Vidrine’s cancer.
The Januvia lawsuit states that research studies have found a risk between the type-2 diabetes drug and pancreatic cancer. These studies date back as far as early 2010. Additionally, there have been reports of pancreatic cancer in patients taking Januvia and related drugs. Vidrine’s Januvia lawsuit alleges that this evidence was sufficient and that it was reasonable to expect that Merck should have been aware of the risks allegedly associated with their drug. The Januvia lawsuit further alleges that Merck continued to actively promote the drug, endangering patients.
Vidrine’s lawsuit may join others in a type of group lawsuit called a multidistrict litigation (MDL) or mass tort. Mass torts are similar to the more familiar class action lawsuit. Both mass torts and class action lawsuits allow a group of people to seek legal redress against the same defendant. Mass torts and class action lawsuits are designed to streamline the legal process.
Mass torts are more common than class action lawsuits in drug lawsuits, because injuries can vary so much. Class action lawsuits typically start out as group lawsuits, while mass torts start as individual lawsuits that are brought together to take advantage of the same resources, making it more manageable for all parties.
The Januvia lawsuit is Roy Allen Vidrine v. Merck Sharp & Dohme Corp., et al., Case No. 3:14-cv-00942-AJB-MDD, in the U.S. District Court for the Western District of Louisiana, Lafayette/Opelousas Division.
The Januvia MDL is In Re: Incretin-Based Therapies Products Liabilities Litigation, MDL No. 2452, in the U.S. District Court for the District of California.
In general, Januvia pancreatic cancer lawsuits are filed individually by each plaintiff and are not class actions.
Do YOU have a legal claim? Fill out the form on this page now for a free, immediate, and confidential case evaluation. The attorneys who work with Top Class Actions will contact you if you qualify to let you know if an individual lawsuit or class action lawsuit is best for you. Hurry — statutes of limitations may apply.
ATTORNEY ADVERTISING
Top Class Actions is a Proud Member of the American Bar Association
LEGAL INFORMATION IS NOT LEGAL ADVICE
Top Class Actions Legal Statement
©2008 – 2024 Top Class Actions® LLC
Various Trademarks held by their respective owners
This website is not intended for viewing or usage by European Union citizens.
Get Help – It’s Free
Join a Free Januvia, Janumet, Byetta, Victoza Cancer Class Action Lawsuit Investigation
If you or your loved one took Januvia, Victoza, Janumet or Byetta and were diagnosed with pancreatic cancer or thyroid cancer, you have a legal claim. See if you qualify by filling out the short form below.
An attorney will contact you if you qualify to discuss the details of your potential case at no charge to you.
Oops! We could not locate your form.
